Julie A. Anderson

Julie A. Anderson

Auto-generated profile, based on publicly available information

Julie A. Anderson

Research and Development, GlaxoSmithKline, Stockley Park, UK

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
Andras BikovAndras Bikov
Andras Bikov
PLPeter Lange
Peter Lange
JAJulie A Anderson
Julie A Anderson
RBRobert D Brook
Robert D Brook
PCPeter Ma Calverley
Peter Ma Calverley
JVJørgen Vestbo
Jørgen Vestbo
Purpose: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide. Impaired lung function is associated with heightened risk for death, cardiovascular events, and COPD exacerbations. However, it is unclear if forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) differ in predictive value. Patients and Methods: Data from 16,485 participants in the Study to Understand Mortality and Morbidity (SUMMIT) in COPD were analyzed. Patients were grouped into quintiles for each lung function parameter (FEV1 %predicted, FVC %predicted, FEV1/FVC). The four highest quintiles (Q2–Q5) were compared to the lowest (Q1) to assess their relationship with all-cause mortality, cardiovascular events, and moderate-to-severe and severe exacerbations. Cox-regression was used, adjusted for age, sex, ethnicity, body-mass index, smoking status, previous exacerbations, cardiovascular disease, treatment, and modified Medical Research Council dyspnea score. Results: Compared to Q1 (< 53.5% FEV1 predicted), increasing FEV1 quintiles (Q2 53.5– 457.5% predicted, Q3 57.5– 461.6% predicted, Q4 61.6– 465.8% predicted, and Q5 ≥ 65.8%) were all associated with significantly decreased all-cause mortality (20% (4– 34%), 28% (13– 40%), 23% (7– 36%), and 30% (15– 42%) risk reduction, respectively). In contrast, a significant risk reduction (21% (4– 35%)) was seen only between Q1 and Q5 quintiles of FVC. Neither FEV1 nor FVC was associated with cardiovascular risk. Increased FEV1 and FEV1/FVC quintiles were also associated with the reduction of moderate-to-severe and severe exacerbations while, surprisingly, the highest FVC quintile was related to the heightened exacerbation risk (28% (8– 52%) risk increase). Conclusion: Our results suggest that FEV1 is a stronger predictor for all-cause mortality than FVC in moderate COPD patients with heightened cardiovascular risk and that subjects with moderate COPD have very different risks.

17 June 2021 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
EBEmily Brigham
Emily Brigham
JAJulie A. Anderson
Julie A. Anderson
RBRobert D. Brook
Robert D. Brook
PCPeter M.A. Calverley
Peter M.A. Calverley
BCBartolome R. Celli
Bartolome R. Celli
RWRobert A. Wise
Robert A. Wise
Populations with COPD demonstrate higher survival in overweight and obese compared with normal weight; the “obesity paradox”. Relationships in less-severe COPD are unclear, as is the impact of cardiovascular risk, and few studies include individuals at extremes of obesity. We examined the relationship between body mass index (BMI; defined as underweight: <20 kg·m−2, normal: 20–25 kg·m−2, overweight: 25– <30 kg·m−2, obese class I: 30– <35 kg·m−2, class II: 35– 40 kg·m−2, suggesting that obesity may not remain protective at the extremes in this population.

23 March 2022 in Journal of Food Science
Verified
Journal Article
Closed access
JWJill K. Winkler‐Moser
Jill K. Winkler‐Moser
JAJulie A. Anderson
Julie A. Anderson
HHHong‐Sik Hwang
Hong‐Sik Hwang

1 October 2006 in Chest
Verified
Journal Article
Open access
GFGary T. Ferguson
Gary T. Ferguson
PCPeter M. Calverley
Peter M. Calverley
JAJulie A. Anderson
Julie A. Anderson
BCBartolome Celli
Bartolome Celli
CJChristine Jenkins
Christine Jenkins
NPNeil Pride
Neil Pride
THE TOWARDS A REVOLUTION IN COPD HEALTH (TORCH) STUDY: FLUTICASONE PROPIONATE/SALMETEROL IS WELL TOLERATED IN PATIENTS WITH COPD OVER 3 YEARS

1 October 2006 in Chest
Verified
Journal Article
Closed access
PJPaul W. Jones
Paul W. Jones
PCPeter M. Calverley
Peter M. Calverley
BCBartolome Celli
Bartolome Celli
JAJulie A. Anderson
Julie A. Anderson
GFGary T. Ferguson
Gary T. Ferguson
NPNeil Pride
Neil Pride

1 October 2006 in Chest
Verified
Journal Article
Open access
BCBartolome Celli
Bartolome Celli
PCPeter M. Calverley
Peter M. Calverley
JAJulie A. Anderson
Julie A. Anderson
GFGary T. Ferguson
Gary T. Ferguson
CJChristine Jenkins
Christine Jenkins
NPNeil Pride
Neil Pride
THE TOWARDS A REVOLUTION IN COPD HEALTH (TORCH) STUDY: FLUTICASONE PROPIONATE/SALMETEROL REDUCES THE RATE OF EXACERBATIONS OVER 3 YEARS